Biotech M&A in 2025: Is a resurgence on the cards?
This issue of our newsletter is supported by Inpart.
The sector struggled with a lack of M&A activity in 2024 as the aggregate value of transactions dropped dramatically compared to 2023. Because of this, last year is largely considered by experts to have been a “reset” year, in which companies chose to focus on bolt-ons and other smaller strategic plays. But there is now big hope for biotech M&A in 2025, with a resounding sense that activity will finally rise again as several important factors come into play.?
One of the key drivers of biotech M&A this year will be the looming patent cliff that awaits many large drugmakers, as well as the evolving political landscape, with the return of Donald Trump as President of the U.S. spurring hopes among dealmakers that 2025 will be a positive year for M&A.?
To find out more, read the full article: “Is biotech M&A set to surge in 2025?”
A MESSAGE FROM OUR SPONSOR INPART
Top 25 innovations for 2025, identified by the global R&D community
Check out Inpart’s annual list of top innovations set to have the biggest impact across science and R&D in the coming year! These are the opportunities that captured the most industry engagement on Connect in 2024, including an approach for diagnosing Alzheimer's and a new CAR therapy for solid tumor cancers.
?? Find it here
Want to advertise with us? Become our next sponsor.
?? More noteworthy articles from this week:
领英推荐
CRISPR-Cas9 is one of the biggest discoveries of the 21st century. Since it was developed in 2012, this gene-editing tool has revolutionized biology research, making it easier to study disease and faster to discover drugs. The technology is also significantly impacting the development of crops, foods, and industrial fermentation processes.
First-in-class drugs are therapies that utilize novel mechanisms of action, offering new approaches to challenging diseases. In 2024, the U.S. Food and Drug Administration (FDA) approved 50 new molecular entities, with 24 designated as first-in-class. But will 2025 do better? Let’s take a closer look at ten first-in-class drugs set to be approved this year.?
Biopharma partnerships fuel significant contributions towards healthcare and drug discovery. The year 2024 ended with several biotechs teaming up to make these therapeutic advancements. December saw antibody-drug conjugates, small molecules, and antibodies in demand. Notably, GSK, Novartis, and Candid Therapeutics stood out with the most number of collaborations.
Various PD-1 and PD-L1 checkpoint inhibitors have been approved by U.S. regulators, including blockbuster drugs Keytruda, Imfinzi, and Opdivo, to treat different types of cancer. But that hasn’t stopped biotechs from advancing their checkpoint inhibitor candidates in the clinic in a bid to beat these approved drugs in both efficacy and safety – the latter of which has been a cause for concern.
Podcasts are a great way to learn and engage listeners with stories that may strike their interest, particularly in the world of biotech. Whether you’re commuting to work, cleaning, going for a walk, doing the laundry, or just sitting down to relax, podcasts can be an ideal way to stay entertained – as well as informed – while multitasking. Here are 14 biotech podcasts that have been gaining traction, thanks to their compelling stories, diverse topics, and innovative formats this year.
Initiate Ventures is shaking up the traditional venture capital model by blending investments in healthcare, life sciences, and technology with a company creation platform. Their approach is reflected in their dual model: funding existing companies while also co-creating ventures alongside founders in their startup studio. This week on the podcast, we have a conversation with one of the co-founders of the company, Jessica Owens.
The biopharma industry’s pursuit of streamlining complex development and manufacturing workflows is driven by process intensification and integration of automation, continuous processing, and single-use system solutions. This strategy is especially relevant in the current landscape, where recent global health crises are directing the adoption of more versatile and economical manufacturing solutions while adhering to stringent regulatory requirements.
??Enjoying these articles??Never miss a single publication of Labiotech by becoming a part of our community! Click here to join our mailing list.